Related Experiment Video
Updated: May 5, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Recent developments in the treatment of renal cell carcinoma
1Associate Director, Cancer Research Foundation, Immediate Past Chair of ECOG-ACRIN Renal Cancer Subcommittee, 750 Kappock Street, # 511, Bronx, NY 10463, USA.
Abstract:
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the understanding of the molecular characterizations of subtypes of RCC with potential to lead to new therapeutic options. Additionally, the urologic oncology community is focusing on nephron-sparing surgical approaches with limited surgery if possible, and in conjunction with interventional radiologists, on ablative procedures for incidentally determined small renal masses. This report reviews some of the new biologic findings of adenocarcinoma of the kidney, and reviews the new therapeutics which continue to change the landscape for treatment of RCC.
Insights
New treatments and molecular insights are transforming renal cell carcinoma (RCC) management. Advances focus on targeted therapies for advanced disease and minimally invasive surgical options for smaller tumors.
Area of Science:
- Oncology
- Urology
- Molecular Biology
Background:
- Renal cell carcinoma (RCC) management is evolving rapidly.
- Recent breakthroughs in treating advanced and metastatic RCC have spurred new interest.
- Understanding the molecular subtypes of RCC is crucial for developing novel therapies.
Purpose of the Study:
- To review recent biological findings in kidney cancer.
- To discuss emerging therapeutic strategies for RCC.
- To highlight advancements in surgical and ablative procedures for renal masses.
Main Methods:
- Review of current literature on RCC.
- Analysis of new molecular characterizations of RCC subtypes.
- Evaluation of novel treatment modalities and surgical techniques.
Main Results:
- Significant progress in systemic therapies for advanced RCC.
- Identification of molecular targets for personalized treatment approaches.
- Increased adoption of nephron-sparing surgery and ablative techniques for small renal masses.
Conclusions:
- Novel therapeutics are significantly altering RCC treatment paradigms.
- Molecular insights are paving the way for targeted treatment options.
- Minimally invasive approaches are becoming standard for small renal masses, improving patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy